PEOPLE/WEB SEARCH CALENDAR EMERGENCY INFO A-Z INDEX UVA EMAIL
RETURN TO U.VA. INNOVATION SEARCH TECHNOLOGIES ADVANCED
SEARCH
SUBSCRIBE
TO RSS

New Platform for Targeted Intravascular Drug and Gene Delivery

Description:

Executive Summary
This novel device combines the imaging capabilities of intravascular ultrasound (IVUS) with the therapeutic effectiveness of targeted microbubbles. The result is a new paradigm for targeted drug and gene delivery that yields safer and more effective treatments. This device also enables treatment of diseases for which therapy is currently limited and not effective, such as peripheral artery disease.

Background
Traditional or systemic treatment of diseases requires dosing patients in excess of the minimum therapeutically effective dose, which can lead to unnecessary off-target effects, such as liver and kidney toxicity. Furthermore, traditional methods often rely on surrogate measures, such as a biomarker, as opposed to real-time imaging to determine effectiveness of a given targeting strategy.

The future of disease treatment lies in the promise of targeted drug and gene delivery. With these methods, only the diseased area is exposed to the therapeutic agent, minimizing patient side effects and allowing the use of more potent and effective therapies.

Invention Description
Researchers at the University of Virginia have developed a new IVUS-based drug delivery platform. The device is novel in that it enables both high- and low-frequency ultrasound, providing high-resolution imaging with combined microbubble therapy. The device is further improved by targeted, local microbubble delivery, which avoids the risks associated with systemic administration.

Initial efforts have been directed towards the delivery of an FDA-approved drug to prevent smooth muscle proliferation associated with in-stent restenosis following angioplasty and stenting. In vivo proof-of-concept studies have demonstrated targeted delivery of multiple agents to various blood vessels.

Advantages
The invention offers the following advantages:

  • Non-invasive device based on proven IVUS methods
  • Integrated imaging providing verification of drug delivery effectiveness and coverage
  • Superior and focused vessel wall therapeutic coverage compared to drug eluting stents
  • Cell-specific, molecularly targeted microbubble carriers enabling lower doses of administered doses and thus fewer side effects


Applications

The invention has applications in the following areas:

  • Targeted drug delivery within the vasculature
  • Treatment of in-stent restenosis
  • Peripheral artery disease

 

Patent Information:
Category(s):
Medical Devices
For Information, Contact:
Christopher Paschall
Licensing Manager
UVA
cdp8x@virginia.edu
Inventors:
John Hossack
Brian Wamhoff
Alexander Klibanov
Brent French
Johnny Chen
Keywords:
Devices
Medical
Home | Search | RSS Feed
Maintained by: U.Va. Innovation
© 2012 by the Rector and Visitors of the University of Virginia
All Rights Reserved. Powered by Inteum
U.Va. Innovation
434.924.2175
434.982.1583
250 W. Main St., Ste. 300
P.O. Box 800755
Charlottesville, VA 22902